Quest Diagnostics Inc
NYSE:DGX
Relative Value
The Relative Value of one
DGX
stock under the Base Case scenario is
202.67
USD.
Compared to the current market price of 200.9 USD,
Quest Diagnostics Inc
is
Undervalued by 1%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
DGX Competitors Multiples
Quest Diagnostics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.1B USD | 2 | 22.4 | 12.4 | 16.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
97B USD | 0.2 | 54.9 | 14 | 14 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
66.4B EUR | 0.3 | 12.9 | 7.6 | 9.7 | |
| US |
|
Cigna Corp
NYSE:CI
|
69.1B USD | 0.3 | 11.6 | 0 | 0 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27B EUR | 1.2 | 21.3 | 9.9 | 14.8 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.4B EUR | 1.2 | 23.9 | 9.2 | 17 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.1B USD | 1.6 | 25.2 | 12.1 | 17.6 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.1B EUR | 0.6 | 11.3 | 5.4 | 10 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.8B USD | 12 | -28.4 | -30.5 | -27.7 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 0.8 | 13.9 | 7.3 | 9.9 | |
| US |
|
Brightspring Health Services Inc
NASDAQ:BTSG
|
7.9B USD | 0 | 0 | 0 | 0 |